References
1. Ineichen BV, Moridi T, Granberg T, Piehl F. Rituximab treatment for multiple sclerosis. Vol. 26, Multiple Sclerosis Journal. SAGE Publications Ltd; 2020. p. 137–52.
2. Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol. 2018;75(3):320–7.
3. Kidoguchi K, Kubota Y, Kusaba K, Kizuka-Sano H, Yamaguchi K, Nishioka A, et al. Severe infusion reaction, anti-rituximab antibodies and lymphoma Learning points for clinicians.
4. Vedala K, Desikan SP, McClain C, Jacob D, Desikan R. Capillary Leak Syndrome From Rituximab Therapy of Lymphoma. J Investig Med High Impact Case Rep. 2020;8.
5. Baker D, Ali L, Saxena G, Pryce G, Jones M, Schmierer K, et al. The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies. Front Immunol. 2020 Feb 14;11:124.
6. Amlani A, Barber C, Fifi-Mah A, Monzon J. Successful Treatment of Cytokine Release Syndrome with IL-6 Blockade in a Patient Transitioning from Immune-Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of Literature. The Oncologist. 2020;25:1120–3.
7. Frey N, Porter D. Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. Vol. 25, Biology of Blood and Marrow Transplantation. Elsevier Inc.; 2019. p. e123–7.
8. Hirano T, Murakami M. COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome. Immunity. 2020 May 19;52(5):731–3.
9. Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome. The Oncologist. 2018 Aug;23(8):943–7.
10. Chavez JC, Jain MD, Kharfan-Dabaja MA. Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading models. Vol. 13, Hematology/ Oncology and Stem Cell Therapy. King Faisal Specialist Hospital and Research Centre; 2020. p. 1–6.
11. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006 Sep 7;355(10):1018–28.
12. Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, Corboy JR, et al. Rituximab-induced serum sickness in multiple sclerosis patients. Mult Scler Relat Disord. 2019;36:101402.
13. Fuentes Fernandez I, Hernandez-Clares R, Carreón Guarnizo E, Meca Lallana JE. Capillary leak syndrome in neuromyelitis optica treated with rituximab. Mult Scler Relat Disord. 2017;16:22–3.
Figure legends :
Figure 1; Fluid-attenuated inversion recovery (FLAIR) cervical spine MRI of the patient revealing a hyperintense lesion at the level of C3-C4.